{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:13:26Z","timestamp":1788246806165,"version":"build-2803163510"},"publisher-location":"Chichester, UK","reference-count":98,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd009868.pub2","type":"reference-entry","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:45Z","timestamp":1397606445000},"source":"Crossref","is-referenced-by-count":42,"title":["Fixed-dose combination therapy for the prevention of cardiovascular disease"],"prefix":"10.1002","author":[{"given":"Angharad N","family":"de Cates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew RB","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag C","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,16]]},"reference":[{"key":"10.1002\/14651858.CD009868.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/01.hjh.0000379022.25815.dc","article-title":"Cardiovascular risk factor management: Single-pill amlodipine\/atorvastatin versus usual care in patients with hypertension and additional risk factors - the CRUCIAL trial","volume":"Conference(vari","author":"Pavia","year":"2010","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/01.hjh.0000379016.95320.39","article-title":"Treatment strategies for cardiovascular risk factor management in patients with hypertension and additional risk factors-experiences from the usual care arm of the CRUCIAL trial","volume":"Conference(vari","author":"Pavia","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1185\/03007995.2011.555754","article-title":"Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial","volume":"27","author":"Zamorano","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1751-7176.2008.00058.x","article-title":"The use of a single-pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: A randomized, placebo-controlled, multicenter study","volume":"11","author":"Neutel","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD009868.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1742-1241.2010.02412.x","article-title":"A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors","volume":"64","author":"Malekzadeh","year":"2010","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"e19857","DOI":"10.1371\/journal.pone.0019857","article-title":"An international randomised placebo-controlled trial of a four-component combination pill (\"polypill\") in people with raised cardiovascular risk","volume":"6","author":"PILL","year":"2011","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD009868.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"12","author":"Soliman","year":"2011","journal-title":"Trials"},{"issue":"9672","key":"10.1002\/14651858.CD009868.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Yusuf","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/VHRM.S7710","article-title":"Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine\/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial","volume":"6","author":"Grimm","year":"2010","journal-title":"Vascular Health & Risk Management"},{"key":"10.1002\/14651858.CD009868.pub2-BIB10|cit10","first-page":"A120","article-title":"The critical importance of treating absolute cardiovascular risk as opposed to individual cardiovascular risk factors in isolation","volume":"Conference(vari","author":"Grimm","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"e41297","DOI":"10.1371\/journal.pone.0041297","article-title":"Randomised polypill crossover trial in people aged 50 and over","volume":"7","author":"Wald","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD009868.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/jc.2011-1309","article-title":"Long-term follow-up for mortality and cancer in a randomized, placebo-controlled trial of vitamin D3 and\/or calcium (RECORD)","volume":"97","author":"Avenell","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD009868.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1229e1","DOI":"10.1016\/j.amjmed.2012.05.023","article-title":"Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil","volume":"125","author":"Bakris","year":"2012","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1524-6175.2005.04533.x","article-title":"Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine\/atorvastatin gemini study)","volume":"7","author":"Blank","year":"2005","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB16|cit16","first-page":"e303","article-title":"Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regiments: population-based case-control study","volume":"340","author":"Bogger-Meiddo","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD009868.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1751-7176.2009.00062.x","article-title":"Amlodipine\/atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus","volume":"11","author":"Ferdinand","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4065\/83.1.35","article-title":"Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine\/atorvastatin in African Americans: the CAPABLE trial","volume":"83","author":"Flack","year":"2008","journal-title":"Mayo Clinics Proceedings"},{"key":"10.1002\/14651858.CD009868.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2261-10-29","article-title":"Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees","volume":"10","author":"Chapman","year":"2010","journal-title":"BMC Cardiovascular Disorders"},{"key":"10.1002\/14651858.CD009868.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2011.11.2492","article-title":"Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension","volume":"123","author":"Chrysant","year":"2011","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD009868.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jash.2012.11.006","article-title":"Variations of some inflammatory markers in hypertensive patients after 1 year of olmesartan\/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies","volume":"7","author":"Derosa","year":"2013","journal-title":"Journal of the American Society of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD009868.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/jhh.2008.114","article-title":"Single-pill amlodipine\/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)","volume":"23","author":"Erdine","year":"2009","journal-title":"Journal of Human Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2005.10.017","article-title":"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine\/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)","volume":"110","author":"Hobbs","year":"2006","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/HJR.0b013e32832b63f5","article-title":"International open-label studies to assess the efficacy and safety of single-pill amlodipine\/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme","volume":"16","author":"Richard Hobbs","year":"2009","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"key":"10.1002\/14651858.CD009868.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3810\/pgm.2011.11.2496","article-title":"Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin","volume":"123","author":"Li","year":"2011","journal-title":"Postgraduate Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009868.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.clinthera.2009.10.015","article-title":"Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea","volume":"31","author":"Liew","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009868.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.curtheres.2012.02.004","article-title":"Long-term tolerability and efficacy of single-pill combinations of telmisartan 40-80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5-10 mg: open-label, long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies","volume":"73","author":"Neldam","year":"2012","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"key":"10.1002\/14651858.CD009868.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1751-7176.2012.00595.x","article-title":"Single-pill combination of telmisartan\/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study","volume":"14","author":"Neutel","year":"2012","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"e8713","DOI":"10.1136\/bmj.e8713","article-title":"Safety of coprescribing NSAIDs with multiple antihypertensive agents: triple drug combinations are associated with increased hospital admission for acute kidney injury, but questions remain","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/11532170-000000000-00000","article-title":"Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers","volume":"10","author":"Patel","year":"2010","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1002\/14651858.CD009868.pub2-BIB31|cit31","first-page":"8","article-title":"Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients","volume":"40","author":"Sun","year":"2012","journal-title":"Chinese Journal of Cardiovascular Disease"},{"key":"10.1002\/14651858.CD009868.pub2-BIB32|cit32","first-page":"463","article-title":"Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases: The second Indian Polycap Study (TIPS-2) investigators","volume":"5","author":"Yusuf","year":"2012","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD009868.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2753.2011.01637.x","article-title":"Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the polypill approach","volume":"18","author":"Wald","year":"2012","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1002\/14651858.CD009868.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/HJH.0b013e3283582ed6","article-title":"Cardiovascular outcomes in hypertensive patients: Comparing single-agent therapy with combination therapy","volume":"30","author":"Weber","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(12)61343-9","article-title":"Effects of body size and hypertension on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial","volume":"381","author":"Weber","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.clinthera.2012.05.007","article-title":"Efficacy and tolerability of initial therapy with single pill combination telmisartan\/hydrochlorothiazide 80\/25 mg in patients with grade 2 or 3 hypertension: a multinational randomized, double blind, active-controlled trial","volume":"34","author":"Zhu","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009868.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ahj.2011.08.012","article-title":"The fixed-dose combination drug for secondary cardiovascular prevention project: study design and objectives","volume":"162","author":"Sanz","year":"2011","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD009868.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.cct.2011.07.006","article-title":"Improving adherence using combination therapy (IMPACT): design and protocol of a RCT in primary care","volume":"32","author":"Selak","year":"2011","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD009868.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/1471-2458-10-458","article-title":"Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD009868.pub2-BIB40|cit40","unstructured":"Polypill and non-alcoholic steatohepatitis (PolyIran-L) Clinicaltrials.gov: NCT01245608"},{"key":"10.1002\/14651858.CD009868.pub2-BIB41|cit41","unstructured":"Prevention of cardiovascular disease in middle-aged and elderly Iranians using a single polypill (PolyIran) Clinicaltrials.gov: NCT01271985"},{"key":"10.1002\/14651858.CD009868.pub2-BIB42|cit42","unstructured":"The International Polycap Study-3 ClinicalTrials.gov Identifier: NCT01646437"},{"issue":"23","key":"10.1002\/14651858.CD009868.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"24","key":"10.1002\/14651858.CD009868.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2010.840","article-title":"Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial","volume":"303","author":"Armitage","year":"2010","journal-title":"JAMA"},{"issue":"7329","key":"10.1002\/14651858.CD009868.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"9493","key":"10.1002\/14651858.CD009868.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9678","key":"10.1002\/14651858.CD009868.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"9775","key":"10.1002\/14651858.CD009868.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(11)60393-0","article-title":"Priority actions for the non-communicable disease crisis","volume":"377","author":"Beaglehole","year":"2011","journal-title":"Lancet"},{"issue":"9435","key":"10.1002\/14651858.CD009868.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"8693","key":"10.1002\/14651858.CD009868.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/HJR.0b013e32832b38a1","article-title":"Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies","volume":"16","author":"Cooney","year":"2009","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1368-5031.2005.00601.x","article-title":"Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine\/atorvastatin single-pill therapy","volume":"59","author":"Cowie","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD009868.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB55|cit55","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001561.pub3","article-title":"Multiple risk factor interventions for primary prevention of coronary heart disease","author":"Ebrahim","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD009868.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009868.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"e52145","DOI":"10.1371\/journal.pone.0052145","article-title":"The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials","volume":"7","author":"Elley","year":"2012","journal-title":"PLoS One"},{"issue":"7480","key":"10.1002\/14651858.CD009868.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bmj.329.7480.1447","article-title":"The polymeal: a more natural, safer, and probably tastier (than the polypill) strategy to reduce cardiovascular disease by more than 75%","volume":"329","author":"Franco","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009868.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB62|cit62","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org"},{"issue":"9791","key":"10.1002\/14651858.CD009868.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(11)60872-6","article-title":"Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials","volume":"378","author":"Holmes","year":"2011","journal-title":"Lancet"},{"issue":"9326","key":"10.1002\/14651858.CD009868.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"HPSCG","year":"2002","journal-title":"Lancet"},{"issue":"9426","key":"10.1002\/14651858.CD009868.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"9607","key":"10.1002\/14651858.CD009868.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD009868.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009868.pub2-BIB68|cit68","unstructured":"Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"20","key":"10.1002\/14651858.CD009868.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","article-title":"The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions","volume":"122","author":"Lonn","year":"2010","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD009868.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"571-81; quiz 82","DOI":"10.1111\/j.1524-6175.2006.05636.x","article-title":"Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial","volume":"8","author":"Messerli","year":"2006","journal-title":"Journal of Clinical Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009868.pub2-BIB72|cit72","unstructured":"NICE Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG67NICEguideline.pdf 2008"},{"key":"10.1002\/14651858.CD009868.pub2-BIB73|cit73","unstructured":"NICE Prevention of cardiovascular disease at population level http:\/\/www.nice.org.uk\/guidance\/PH25 2010"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/HJH.0b013e328310e0d9","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes","volume":"26","author":"Ostergren","year":"2008","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD009868.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1524-6175.2003.03163.x","article-title":"Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"5","author":"Papademetriou","year":"2003","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub2-BIB77|cit77","first-page":"1635","article-title":"European Guidelines on cardiovascular diseaseprevention in clinical practice (version 2012)","volume":"33","author":"Perk","year":"2012","journal-title":"European Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"e19857","DOI":"10.1371\/journal.pone.0019857","article-title":"An international randomised placebo-controlled trial of a four-component combination pill (\"polypill\") in people with raised cardiovascular risk","volume":"6","author":"Rodgers","year":"2011","journal-title":"Plos One"},{"issue":"12","key":"10.1002\/14651858.CD009868.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/0091270007307879","article-title":"A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial","volume":"47","author":"Preston","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/01.STR.0000092488.40085.15","article-title":"Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review","volume":"34","author":"Rashid","year":"2003","journal-title":"Stroke"},{"issue":"9364","key":"10.1002\/14651858.CD009868.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub2-BIB82|cit82","first-page":"[Epub ahead of","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"Nov 12","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009868.pub2-BIB83|cit83","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease.","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/euhj.2001.2888","article-title":"Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young","volume":"23","author":"Thomas","year":"2002","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD009868.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","year":"2009","journal-title":"Lancet"},{"issue":"9395","key":"10.1002\/14651858.CD009868.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ije\/dyp330","article-title":"Thirty-five-year trends in cardiovascular risk factors in Finland","volume":"39","author":"Vartiainen","year":"2010","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ypmed.2010.09.016","article-title":"Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians","volume":"52","author":"Viera","year":"2011","journal-title":"Preventive Medicine"},{"key":"10.1002\/14651858.CD009868.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"e002498","DOI":"10.1136\/bmjopen-2012-002498","article-title":"Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study","volume":"3","author":"Virdee","year":"2013","journal-title":"BMJ Open"},{"issue":"7404","key":"10.1002\/14651858.CD009868.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ypmed.2010.11.015","article-title":"The polypill in the prevention of cardiovascular disease","volume":"52","author":"Wald","year":"2011","journal-title":"Preventive Medicine"},{"key":"10.1002\/14651858.CD009868.pub2-BIB92|cit92","unstructured":"World Health Organization Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Report of WHO-Wellcome Trust meeting of experts (1-3 August 2001) Geneva: World Health Organization 2002"},{"key":"10.1002\/14651858.CD009868.pub2-BIB93|cit93","unstructured":"World Health Organization Global Health Observatory Data Respository Available from http:\/\/apps.who.int\/ghodata."},{"key":"10.1002\/14651858.CD009868.pub2-BIB94|cit94","unstructured":"World Health Organization Global status report on noncommunicable diseases Geneva: World Health Organization, 2010 (a)"},{"key":"10.1002\/14651858.CD009868.pub2-BIB95|cit95","unstructured":"World Health Organization Global status report on noncommunicable diseases 2010 Geneva: World Health Organization 2011"},{"issue":"9326","key":"10.1002\/14651858.CD009868.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","article-title":"Two decades of progress in preventing vascular disease","volume":"360","author":"Yusuf","year":"2002","journal-title":"Lancet"},{"issue":"9438","key":"10.1002\/14651858.CD009868.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"9798","key":"10.1002\/14651858.CD009868.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009868.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009868.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:37:44Z","timestamp":1628548664000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009868.pub2"}},"subtitle":[],"editor":[{"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,16]]},"references-count":98,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009868.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD009868.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2014,4,16]]}}}